News | May 03, 2024
Moderna posts Q1 2024 revenues at US$167 million
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Submission based on results from pivotal phase III trial showing all primary endpoints met
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
The company plans to add 1700 beds by FY27 through the organic route
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
Executes the first project for developing and manufacturing a novel anticancer mAb
Subscribe To Our Newsletter & Stay Updated
